TMCnet - World's Largest Communications and Technology Community



Research and Markets: The Netherlands Healthcare, Regulatory and Reimbursement Landscape - Key Analysis of the Multi-Billion market
[September 05, 2014]

Research and Markets: The Netherlands Healthcare, Regulatory and Reimbursement Landscape - Key Analysis of the Multi-Billion market

DUBLIN --(Business Wire)--

Research and Markets ( has announced the addition of the "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - The Netherlands" report to their offering.

The value of the pharmaceutical market in the Netherlands was estimated at $6.7 billion in 2013

Specific therapeutic segments, such as cardiovascular, anticancer and gastrointestinal drugs, dominate the market. In order to reduce the healthcare deficit, the government is focusing on the use of generics as a cost-containment tool. The increasingly elderly population and the corresponding increase in the incidence of chronic diseases will help to boost the growth in the pharmaceutical market. It is expected to grow at a steady Compound Annual Growth Rate (CAGR) of 0.9% from $6.7 billion in 2014 to $7.2 billion in 2020.

The 2008-2012 period saw an increase in ependiture on expensive medicines (medicines priced at more than 500 ($670.4)), and in 2011, the revenue generated from their sale increased by 107m ($143.4m) to 1.11 billion ($1.49 billion) (SFK, 2012). However, expenditure on expensive medicines within pharmaceutical care declined in 2012 due to the transfer of the financing of drugs such as Tumor Necrosis Factor (TNF)-alfa inhibitors and associated medicines to the reimbursement list of medicines, as lay out by that year's hospital budget and based on the cost of the drugs alone. From 2013, other drugs such as oncology drugs and growth hormones may also be transferred to the hospitals' budget from community pharmacies.

The Ministry of Health, Welfare and Sport (MoHWS) sets the prices for medicines twice a year (in April and October). The Drug Price Act (Wet Geneesmiddelenprijzen, WGP) has played an important role in pricing since its introduction in 1996. Continual price cuts have seen drug prices decline by an average of 3-4% per year, and from 1996 to 2012, prices declined by 50% (SFK, 2012). The price regulations aimed at cost-containment have had a negative impact on the pharmaceutical market.

In 2013, the medical device market in the Netherlands was valued at $3.2 billion, having grown at a CAGR of 4.4% from $2.6 billion in 2008. In 2013, the major segments were cardiovascular devices (13.1%), ophthalmic devices (12.1%), In Vitro Diagnostics (IVD) (11.9%), orthopedic devices (11.3%), and hospital supplies (6.0%). The market is driven by factors such as increasing awareness regarding the early detection and diagnosis of disease, advancements in medical technology, and an increase in the elderly population.

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Overview of Pharmaceutical and Medical Device Markets

4 Market Access

5 Country Analysis

6 Opportunities and Challenges

7 Appendix

For more information visit

[ Back To's Homepage ]

Technology Marketing Corporation

35 Nutmeg Drive Suite 340, Trumbull, Connecticut 06611 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments:
Comments about this site:


© 2018 Technology Marketing Corporation. All rights reserved | Privacy Policy